Q2 2026 Holdings
Filed 2026-08-14 | 44 holdings | $3.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $555.3M | 2,965,160 | 14.2% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $444.0M | 3,872,052 | 11.4% |
| Xoma Royalty Corporation(XOMA) | COM NEW | 98419J206 | $322.7M | 7,593,303 | 8.3% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $311.5M | 16,001,284 | 8.0% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $232.5M | 8,650,158 | 5.9% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $180.7M | 3,366,823 | 4.6% |
| Nektar Therapeutics(NKTR) | COM NEW | 640268306 | $166.9M | 2,391,075 | 4.3% |
| Mirum Pharmaceuticals Inc(MIRM) | COM | 604749101 | $123.6M | 1,056,027 | 3.2% |
| Xencor Inc(XNCR) | COM | 98401F105 | $114.9M | 7,133,720 | 2.9% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $112.9M | 2,154,704 | 2.9% |
| Monte Rosa Therapeutics Inc(GLUE) | COM | 61225M102 | $108.0M | 4,460,886 | 2.8% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $104.7M | 5,750,683 | 2.7% |
| Palvella Therapeutics Inc NE(PVLA) | COM | 697947109 | $102.8M | 672,789 | 2.6% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $95.4M | 3,649,142 | 2.4% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $92.7M | 8,445,769 | 2.4% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $84.4M | 1,153,612 | 2.2% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $83.4M | 2,547,557 | 2.1% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $66.3M | 5,295,893 | 1.7% |
| Annexon Inc(ANNX) | COM | 03589W102 | $49.7M | 8,698,173 | 1.3% |
| Crescent Biopharma Inc.(CBIO) | COM | G2545C104 | $49.5M | 2,748,763 | 1.3% |
| AC Immune SA(ACIU) | SHS | H00263105 | $47.2M | 19,822,436 | 1.2% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $47.1M | 1,476,196 | 1.2% |
| Sutro Biopharma Inc(STRO) | COM SHS | 869367201 | $41.6M | 1,251,788 | 1.1% |
| Immunocore Hldgs PLC(IMCR) | ADS | 45258D105 | $41.1M | 1,294,463 | 1.1% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $38.4M | 2,075,545 | 1.0% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $38.3M | 2,879,289 | 1.0% |
| Q32 BIO Inc(QTTB) | COM | 746964105 | $29.9M | 2,350,000 | 0.8% |
| Anteris Technologies Global(AVR) | COM | 03675P102 | $29.6M | 3,000,000 | 0.8% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $28.5M | 5,842,000 | 0.7% |
| Absci Corporation(ABSI) | COM | 00091E109 | $27.4M | 2,361,674 | 0.7% |
| Eledon Pharmaceuticals Inc(ELDN) | COM | 28617K101 | $24.8M | 6,293,282 | 0.6% |
| Invivyd Inc(IVVD) | COM | 00534A102 | $24.6M | 28,165,000 | 0.6% |
| Sagimet Biosciences Inc(SGMT) | COM SER A | 786700104 | $19.3M | 2,500,000 | 0.5% |
| Onkure Therapeutics Inc(OKUR) | COM CL A | 68277Q105 | $14.8M | 3,235,778 | 0.4% |
| Immunic Inc(IMUX) | COM NEW | 4525EP200 | $11.8M | 765,295 | 0.3% |
| X4 Pharmaceuticals Inc(XFOR) | COM NEW | 98420X202 | $10.4M | 2,233,742 | 0.3% |
| Imagenebio Inc(IMA) | COM | 45175G207 | $6.5M | 1,110,002 | 0.2% |
| Tscan Therapeutics Inc(TCRX) | COM | 89854M101 | $5.5M | 5,564,290 | 0.1% |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | $5.4M | 500,000 | 0.1% |
| Molecular Partners AG(MOLN) | ADS | 60853G106 | $5.1M | 1,353,968 | 0.1% |
| Tenax Therapeutics Inc(TENX) | COM NEW | 88032L605 | $4.9M | 339,549 | 0.1% |
| Entera BIO LTD(ENTX) | SHS | M40527109 | $4.3M | 2,425,000 | 0.1% |
| Inventiva SA(IVA) | ADS | 46124U107 | $2.6M | 686,040 | 0.1% |
| Engene Therapeutics | *W EXP 10/31/202 | 29286X119 | $274.1K | 945,402 | 0.0% |